One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The 50% reduction applies to initiation, titration and maintenance, not just the final daily dose.
What to reconcile: Confirm the exact product, indication, renal measure and full source before prescribing.
Open this note and its source referencesConfirm the exact product, indication, renal measure and full source before prescribing.
Dialysis evidence: No dialysis regimen established in selected content
A percentage reduction does not replace the age/weight-specific starting regimen. Do not abruptly discontinue.
Monitor sodium when appropriate and assess symptoms of hyponatremia. Concomitant antiseizure-drug interactions require separate review.
No new official-label card was obtained for this product in v6.3. Earlier source layers, if present, were retained but not rechecked.
| CrCl, mL/min | Source-specific dose / instruction |
|---|---|
| <50 | Generally reduce initial, titration and maintenance dosages by 50%; individualize to response |
APTIOM renal modification
| CrCl, mL/min | Source-specific dose / instruction |
|---|---|
| <50 | Generally reduce initial, titration and maintenance dosages by 50%; individualize to response |
A percentage reduction does not replace the age/weight-specific starting regimen. Do not abruptly discontinue.
Monitor sodium when appropriate and assess symptoms of hyponatremia. Concomitant antiseizure-drug interactions require separate review.
RDM63-rxlist-eslicarbazepine-9be76c97af-C1 · Source locator: Dosage modifications in renal impairment; hyponatremia; discontinuation
A percentage reduction does not replace the age/weight-specific starting regimen. Do not abruptly discontinue.
Monitor sodium when appropriate and assess symptoms of hyponatremia. Concomitant antiseizure-drug interactions require separate review.
No new official-label card was obtained for this product in v6.3. Earlier source layers, if present, were retained but not rechecked.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=eslicarbazepine&s1=RDM63-rxlist-eslicarbazepine-9be76c97af&h1=cb5c17833e275db25ccea151b6d2ac67de4abe46646c7f1f3ed2320750aa53ff